Sodium zirconium cyclosilicate in HFrEF and hyperkalemia: REALIZE-K design and baseline characteristics
Squire, Iain
Squire, Iain
Abstract
Background: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF). However, MRAs are often underused because of hyperkalemia concerns.
Objectives: The purpose of this study was to assess whether sodium zirconium cyclosilicate (SZC), a nonabsorbed crystal that traps and rapidly lowers potassium, enables MRA use in patients with HFrEF and prevalent hyperkalemia (or at high risk).
Methods: REALIZE-K is a prospective, double-blind, placebo-controlled trial in patients with HFrEF (NYHA functional class II-IV; left ventricular ejection fraction ≤40%), optimal therapy (except MRA), and prevalent hyperkalemia (or at high risk). During the open-label run-in, all participants underwent protocol-mandated spironolactone titration (target: 50 mg daily); those with prevalent (cohort 1) or incident (cohort 2) hyperkalemia during titration started SZC. Participants achieving normokalemia while on spironolactone ≥25 mg daily were randomized to continuing SZC or matching placebo for 6 months. The primary composite endpoint was proportion of participants with optimal response (normokalemia, on spironolactone ≥25 mg daily, no rescue for hyperkalemia [months 1-6]).
Results: Of 365 patients (run-in), 202 were randomized. Baseline characteristics included mean age 70 years, prevalent comorbidities (78% estimated glomerular filtration rate <60 mL/min/1.73 m2, 38% atrial fibrillation/flutter), high N-terminal pro B-type natriuretic peptide (median 1,136 pg/mL), and high HFrEF therapy use (64% sacubitril/valsartan, 96% beta-blocker, 42% sodium glucose co-transporter 2 inhibitor). At randomization, 78% were receiving spironolactone 50 mg daily.
Conclusions: REALIZE-K is the first trial to evaluate whether SZC can enable rapid and safe MRA optimization and long-term continuation in patients with HFrEF and prevalent/high risk of hyperkalemia. (Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients with Symptomatic HFrEF Receiving Spironolactone; NCT04676646).
MIDER Authors
Citations
Altmetric:
Date
2024-05-13
Type
Article
Subject
guideline-directed medical therapy, heart failure, hyperkalemia, mineralocorticoid receptor antagonists, sodium zirconium silicate
Collections
Citation
Kosiborod, M. N., Cherney, D., Connelly, K., Desai, A. S., Guimarães, P. O., Kuthi, L., Lala, A., Madrini, V., Jr, Merkely, B., Villota, J. N., Squire, I., Testani, J. M., Vaclavik, J., Verma, S., Wranicz, J., Dahl, M., Eudicone, J. M., Friberg, L., & Petrie, M. C. (2024). Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics. JACC. Heart failure, S2213-1779(24)00400-1. Advance online publication. https://doi.org/10.1016/j.jchf.2024.05.003